PT2796550T - Novo anticorpo ctgf anti-humano - Google Patents

Novo anticorpo ctgf anti-humano

Info

Publication number
PT2796550T
PT2796550T PT128607421T PT12860742T PT2796550T PT 2796550 T PT2796550 T PT 2796550T PT 128607421 T PT128607421 T PT 128607421T PT 12860742 T PT12860742 T PT 12860742T PT 2796550 T PT2796550 T PT 2796550T
Authority
PT
Portugal
Prior art keywords
novel anti
ctgf antibody
human ctgf
human
antibody
Prior art date
Application number
PT128607421T
Other languages
English (en)
Portuguese (pt)
Inventor
Iwasaki Shoji
Moriya Ryuichi
Yoshino Masayasu
Takakura Koji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT2796550T publication Critical patent/PT2796550T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT128607421T 2011-12-22 2012-12-21 Novo anticorpo ctgf anti-humano PT2796550T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22

Publications (1)

Publication Number Publication Date
PT2796550T true PT2796550T (pt) 2018-04-18

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128607421T PT2796550T (pt) 2011-12-22 2012-12-21 Novo anticorpo ctgf anti-humano

Country Status (16)

Country Link
US (1) US9587015B2 (cg-RX-API-DMAC7.html)
EP (1) EP2796550B1 (cg-RX-API-DMAC7.html)
JP (1) JP6040943B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140107507A (cg-RX-API-DMAC7.html)
CN (1) CN104011206B (cg-RX-API-DMAC7.html)
AR (1) AR089425A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014015405A2 (cg-RX-API-DMAC7.html)
CA (1) CA2859627A1 (cg-RX-API-DMAC7.html)
EA (1) EA029290B1 (cg-RX-API-DMAC7.html)
ES (1) ES2665851T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04615A (cg-RX-API-DMAC7.html)
MX (1) MX345019B (cg-RX-API-DMAC7.html)
PL (1) PL2796550T3 (cg-RX-API-DMAC7.html)
PT (1) PT2796550T (cg-RX-API-DMAC7.html)
TW (1) TW201333034A (cg-RX-API-DMAC7.html)
WO (1) WO2013094723A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
US20220324953A1 (en) * 2019-06-04 2022-10-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-connective tissue growth factor antibody and application thereof
KR20230117161A (ko) * 2020-12-03 2023-08-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-결합 조직 성장 인자 항체를 포함하는 약학 조성물
EP4537841A1 (en) 2022-06-07 2025-04-16 Astellas Pharma, Inc. Pharmaceutical composition containing anti-integrin alpha-11 antibody for treatment or prevention of aging-related diseases
TW202434302A (zh) 2022-10-31 2024-09-01 日商安斯泰來製藥股份有限公司 包含類鐸受體７／８雙重促效劑化合物之抗體藥物複合體
WO2024188179A1 (zh) * 2023-03-10 2024-09-19 上海济煜医药科技有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
AU681633B2 (en) 1993-03-11 1997-09-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
EP1140964B1 (en) * 1998-12-14 2008-04-09 University Of Miami Connective tissue growth factor (ctgf) fragment
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
CA2859627A1 (en) 2013-06-27
EP2796550A4 (en) 2015-08-19
MX345019B (es) 2017-01-11
JP6040943B2 (ja) 2016-12-07
CN104011206A (zh) 2014-08-27
ES2665851T3 (es) 2018-04-27
AR089425A1 (es) 2014-08-20
TW201333034A (zh) 2013-08-16
CN104011206B (zh) 2017-03-08
IN2014CN04615A (cg-RX-API-DMAC7.html) 2015-09-18
KR20140107507A (ko) 2014-09-04
EP2796550A1 (en) 2014-10-29
BR112014015405A2 (pt) 2017-06-13
US20140343258A1 (en) 2014-11-20
JPWO2013094723A1 (ja) 2015-04-27
WO2013094723A1 (ja) 2013-06-27
US9587015B2 (en) 2017-03-07
EP2796550B1 (en) 2018-02-28
PL2796550T3 (pl) 2018-08-31
MX2014007681A (es) 2014-11-25
EA029290B1 (ru) 2018-03-30
EA201491240A1 (ru) 2014-11-28

Similar Documents

Publication Publication Date Title
IL259826A (en) Anti-alphabetatisiar antibody
ZA201400768B (en) Interleukin-31 monoclonal antibody
ZA201307983B (en) Anti-b7-h3 antibody
IL220404A (en) Antiseptic antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201400741B (en) Novel anti-human ngf antibody
TWI563004B (en) Anti-hxcr1 antibody
PL2695897T3 (pl) Nowe przeciwciało przeciwko ludzkiemu receptorowi il-23
PT2796550T (pt) Novo anticorpo ctgf anti-humano
EP2694539A4 (en) POLYCLONAL ANTIBODY COMPOSITIONS
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
PL2821416T3 (pl) Nowe przeciwciało przeciwko ludzkiemu receptorowi IL-23
EP2714074A4 (en) ANTIBODIES AGAINST EMR1